Curative Effect Observation of Anlotinib in Treatment of Advanced Non-Small Cell Lung Cancer
Objective To observe safety of anlotinib in treatment of advanced non-small cell lung cancer(NSCLC).Methods The paper chose 21 patients with advanced NSCLC from June 2020 to June 2021 as observation group,treated with third line treatment with anlotinib,and 21 advanced NSCLC patients at the same time as control group,with gemcitabine monotherapy.Curative effect between two groups was observed,followed up for 6 months,prognosis between two groups was observed.Results Total effective rate of clinical effect after treatment in observation group was 19.05%,that in control group was 4.76%.Disease control rate in observation group was 90.48%,that in control group was 61.90%.Difference between groups showed P<0.05.Comparison of incidence of various adverse reactions between two groups after treatment showed P>0.05.PFS rate after 6 months and OS rate after 8 months in observation group was significantly higher than control group,difference between groups showed P<0.05.Conclusion Anlotinib can achieve better curative effect and relatively better prognosis for patients with advanced NSCLC than gemcitabine only.
NETL
NSTL
万方数据
